信立泰：SAL0137获临床试验批准通知书

Core Viewpoint - The company, Xinlitai (002294), has received approval from the National Medical Products Administration for clinical trials of its innovative small molecule drug SAL0137 tablets aimed at treating elevated lipoprotein(a) levels [1] Group 1 - The approval allows the company to proceed with clinical trials for SAL0137, which is a significant step in the drug development process [1] - SAL0137 is an innovative small molecule drug developed independently by the company [1]